Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
PHP Toggle Menu

Category: TG1050

Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B

20171017 PR AASLD TG1050 final

Published 17 October 2017
Categorized as 2017, Press release, TG1050

Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade

Laetitia Fend, et al.AACR, American Association for cancer Research, April 2017Download the poster herePoster Presentation

Published 5 April 2017
Categorized as -others, 2017, Publication, TG1050

TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.

Roland Kratzer, et al. AASLD & Hepatology, October 2016 – DOI: 10.1002/hep.28800 Download the poster here Poster Presentation

Published 14 November 2016
Categorized as -others, 2017, Publication, TG1050 Tagged Poster presentation, Therapeutic Vaccine

Transgene presents preclinical results of TG1050, an HBV-targeted immunotherapy, at AASLD 2016 Liver Meeting

20161114-poster-hbv_aasld-en

Published 14 November 2016
Categorized as 2016, Press release, TG1050

First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients

20161017-tg1050-md-us-final

Published 17 October 2016
Categorized as 2016, Press release, TG1050

Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee

20160721 – Safety TG1050 EN Vdef

Published 21 July 2016
Categorized as 2016, Press release, TG1050

Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection

20151103 TG1050 FINAL VERSION US

Published 4 November 2015
Categorized as 2015, Press release, TG1050

Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.

Ophelie Godon, et al. Vaccine. 2015 Aug 26;33(36):4548-53 – Download the article Publication

Published 18 September 2015
Categorized as -others, 2015, Publication, TG1050

TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models

Karine Lélu, et al. Journal of Hepatology, April 2015, Volume 62, Supplement 2, Page S205 – Download the article Publication

Published 30 April 2015
Categorized as -others, 2015, Publication, TG1050

TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models

Karine Lélu, et al. EASL Liver Congress 2015, Vienna-23th April 2015 Download the poster here Poster Presentation

Published 30 April 2015
Categorized as -others, 2015, Publication, TG1050

Posts pagination

Newer posts Page 1 Page 2 Page 3 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
Menu